# TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

> **NCT00077883** · PHASE1,PHASE2 · COMPLETED · sponsor: **Telik** · enrollment: 50 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** TLK286, cisplatin

## Key facts

- **NCT ID:** NCT00077883
- **Lead sponsor:** Telik
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2011-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00077883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00077883, "TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00077883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*